199 related articles for article (PubMed ID: 23686804)
21. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
[TBL] [Abstract][Full Text] [Related]
22. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
23. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
24. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
25. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis.
Bellizzi AM; Bloomston M; Zhou XP; Iwenofu OH; Frankel WL
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):442-7. PubMed ID: 20661135
[TBL] [Abstract][Full Text] [Related]
26. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
27. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
28. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
29. STK33 Promotes the Growth and Progression of Human Pancreatic Neuroendocrine Tumour via Activation of the PI3K/AKT/mTOR Pathway.
Zhou B; Xiang J; Zhan C; Liu J; Yan S
Neuroendocrinology; 2020; 110(3-4):307-320. PubMed ID: 31261148
[TBL] [Abstract][Full Text] [Related]
30. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
31. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
32. Loss of PTEN expression in neuroendocrine pancreatic tumors.
Krausch M; Raffel A; Anlauf M; Schott M; Willenberg H; Lehwald N; Hafner D; Cupisti K; Eisenberger CF; Knoefel WT
Horm Metab Res; 2011 Nov; 43(12):865-71. PubMed ID: 22105477
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma.
Lu J; Pan Y; Xia X; Gu Y; Lei Y
Biomed Res Int; 2015; 2015():417210. PubMed ID: 26357655
[TBL] [Abstract][Full Text] [Related]
34. Loss of PTEN and Increased pAKT Expression Distinguishes Aggressive Low-grade Neuroendocrine Tumors.
Jayakumar R; Lanjewar S; Axiotis CA
Ann Clin Lab Sci; 2018 Sep; 48(5):565-572. PubMed ID: 30373859
[TBL] [Abstract][Full Text] [Related]
35. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma.
Monteiro LS; Delgado ML; Ricardo S; Garcez F; do Amaral B; Warnakulasuriya S; Lopes C
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 May; 115(5):638-45. PubMed ID: 23601218
[TBL] [Abstract][Full Text] [Related]
37. A single institution's 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factors.
Cienfuegos JA; Rotellar F; Salguero J; Ruiz-Canela M; Núñez Córdoba JM; Sola I; Benito A; Martí-Cruchaga P; Zozaya G; Pardo F; Hernández Lizoáin JL
Rev Esp Enferm Dig; 2016 Nov; 108(11):689-696. PubMed ID: 27701882
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.
Gonzalez-Roibon ND; Chaux A; Al-Hussain T; Osunkoya AO; Bezerra SM; Hicks J; Epstein JI; Netto GJ
Hum Pathol; 2013 Apr; 44(4):612-22. PubMed ID: 23084634
[TBL] [Abstract][Full Text] [Related]
39. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
40. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
